Title 41, Public Health

For purposes of conducting an ibogaine drug development clinical trial under this chapter, only an institution of higher learning or a hospital may serve as a trial site.

(1) The department and consortium members may solicit and accept gifts, grants, and donations of any kind received from sources other than the state for purposes of funding the drug development clinical trial under this chapter. (2) Disbursements of funds by the department may be…

(1) A consortium selected to conduct the ibogaine drug development clinical trial shall quarterly prepare and submit to the department:(a) A report on the progress of the drug development clinical trial conducted under this chapter; and(b) A financial status report, including inf…

(1) The revenue attributable to all intellectual property rights and other commercial rights arising from the drug development clinical trial conducted by a consortium under this act during the period for which the trial is funded and any following period of commercialization sha…

(1) This section applies only if ibogaine is approved by the FDA to treat a medical condition. (2) A physician licensed in this state who has prescribed ibogaine for a patient shall supervise the administration of ibogaine at a hospital or other licensed health care facility to e…

If before implementing any provision of this chapter, the department or another state agency determines that a waiver or authorization from a federal agency is necessary for implementation of that provision, the agency affected by the provision shall request the waiver or authori…

(a) As used in this chapter, the following terms shall be defined as provided in this section:(a) “Department” means the State Department of Health.(b) “Drug developer” means a pharmaceutical company, biotechnology company, or contract development and manufacturing organization e…

(1) A consortium may be established under this section and apply for selection by the department under this chapter to conduct a drug development clinical trial with ibogaine and secure the FDA’s approval of ibogaine as a medication for the treatment of:(a) Opioid use disorder;(b…

(1) A consortium established under this chapter shall select a lead institution of higher learning from among the consortium’s members to represent the consortium and perform administrative functions under this act, including contracting with and reporting to the department as re…

(1) The lead institution of higher learning of a consortium shall submit to the department a proposal for purposes of conducting an ibogaine drug development clinical trial in accordance with this chapter. (2) A proposal submitted under subsection (1) of this section must provide…